Induction of human cytochrome P450 3A4 by the irreversible myeloperoxidase inactivator PF-06282999 is mediated by the pregnane X receptor

References

• Aninat C, Piton A, Glaise D, et al. (2006). Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75–83
   PubMed Web of Science ®Google Scholar
• Baciewicz AM, Chrisman CR, Finch CK, Self TH. (2008). Update on rifampin and rifabutin drug interactions. Am J Med Sci 335:126–36
   PubMed Web of Science ®Google Scholar
• Backman JT, Olkkola KT, Neuvonen PJ. (1996). Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7–13
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Pena A, et al. (2009). Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309–17
   PubMed Web of Science ®Google Scholar
• Dansette PM, Rosi J, Bertho G, Mansuy D. (2012). Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol 25:348–56
   PubMed Web of Science ®Google Scholar
• Dong J, Gosset J, Fahmi O, et al. (2017). Examination of the human cytochrome P4503A4 induction potential of PF-06282999, an irreversible myeloperoxidase inactivator: integration of preclinical, in silico, and biomarker methodologies in the prediction of the clinical outcome. Drug Metab Dispos 45:501–11
   PubMed Web of Science ®Google Scholar
• Dong JQ, Varma MV, Wolford A, et al. (2016). Pharmacokinetics and disposition of the thiouracil derivative PF-06282999, an orally bioavailable, irreversible inactivator of myeloperoxidase enzyme, across animals and humans. Drug Metab Dispos 44:209–19
   PubMed Web of Science ®Google Scholar
• Evans RM. (2005). The nuclear receptor superfamily: a rosetta stone for physiology. Mol Endocrinol 19:1429–38
   PubMed Web of Science ®Google Scholar
• Fahmi AM, Abdelsamad O, Elewa H. (2016). Rifampin–warfarin interaction in a mitral valve replacement patient receiving rifampin for infective endocarditis: a case report. Springerplus 5:8
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Maurer TS, Kish M, et al. (2008). A combined model for predicting CYP3A4 clinical net drug–drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698–708
   PubMed Web of Science ®Google Scholar
• Fotsch C, Bartberger MD, Bercot EA, et al. (2008). Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic model. J Med Chem 51:7953–67
   PubMed Web of Science ®Google Scholar
• Gao YD, Olson SH, Balkovec JM, et al. (2007). Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach. Xenobiotica 37:124–38
   PubMed Web of Science ®Google Scholar
• Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, et al. (2001). Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 29:242–51
   PubMed Web of Science ®Google Scholar
• Goodwin B, Gauthier KC, Umetani M, et al. (2003). Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc Natl Acad Sci USA 100:223–8
   PubMed Web of Science ®Google Scholar
• Goodwin B, Hodgson E, D'Costa DJ, et al. (2002). Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol 62:359–65
   PubMed Web of Science ®Google Scholar
• Goodwin B, Moore LB, Stoltz CM, et al. (2001). Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60:427–31
   PubMed Web of Science ®Google Scholar
• Harper S, Avolio S, Pacini B, et al. (2005). Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase. J Med Chem 48:4547–57
   PubMed Web of Science ®Google Scholar
• Honkakoski P, Zelko I, Sueyoshi T, Negishi M. (1998). The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol 18:5652–8
   PubMed Web of Science ®Google Scholar
• Jones SA, Moore LB, Shenk JL, et al. (2000). The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27–39
   PubMed Web of Science ®Google Scholar
• Judge HM, Patil SB, Buckland RJ, et al. (2010). Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel. J Thromb Haemost 8:1820–7
   PubMed Web of Science ®Google Scholar
• Kaizerman JA, Aaron W, An S, et al. (2010). Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines. Bioorg Med Chem Lett 20:4607–10
   PubMed Web of Science ®Google Scholar
• Kandel BA, Thomas M, Winter S, et al. (2016). Genomewide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPARalpha in primary human hepatocytes. Biochim Biophys Acta 1859:1218–27
   PubMed Web of Science ®Google Scholar
• Kanebratt KP, Andersson TB. (2008). HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36:137–45
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, et al. (2010). Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92–9
   PubMed Web of Science ®Google Scholar
• Khan JA, Camac DM, Low S, et al. (2015). Developing Adnectins that target SRC co-activator binding to PXR: a structural approach toward understanding promiscuity of PXR. J Mol Biol 427:924–42
   PubMed Web of Science ®Google Scholar
• Kim KY, Epplen K, Foruhari F, Alexandropoulos H. (2007). Update on the interaction of rifampin and warfarin. Prog Cardiovasc Nurs 22:97–100
   PubMedGoogle Scholar
• Kliewer SA, Goodwin B, Willson TM. (2002). The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687–702
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Moore JT, Wade L, et al. (1998). An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73–82
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Yamagami S, Higuchi T, et al. (2004). Key structural features of ligands for activation of human pregnane X receptor. Drug Metab Dispos 32:468–72
   PubMed Web of Science ®Google Scholar
• Le Vee M, Jigorel E, Glaise D, et al. (2006). Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 28:109–17
   PubMed Web of Science ®Google Scholar
• Ledirac N, De Sousa G, Fontaine F, et al. (2000). Effects of macrolide antibiotics on CYP3A expression in human and rat hepatocytes: interspecies differences in response to troleandomycin. Drug Metab Dispos 28:1391–3
   PubMed Web of Science ®Google Scholar
• Lee CR, Thrasher KA. (2001). Difficulties in anticoagulation management during coadministration of warfarin and rifampin. Pharmacotherapy 21:1240–6
   PubMed Web of Science ®Google Scholar
• Lehmann JM, Mckee DD, Watson MA, et al. (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016–23
   PubMed Web of Science ®Google Scholar
• Loboz KK, Gross AS, Williams KM, et al. (2006). Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 80:75–84
   PubMed Web of Science ®Google Scholar
• Luo G, Cunningham M, Kim S, et al. (2002). CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795–804
   PubMed Web of Science ®Google Scholar
• Marschall HU, Wagner M, Zollner G, et al. (2005). Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129:476–85
   PubMed Web of Science ®Google Scholar
• Martins MA, Reis AM, Sales MF, et al. (2013). Rifampicin–warfarin interaction leading to macroscopic hematuria: a case report and review of the literature. BMC Pharmacol Toxicol 14:27
   PubMed Web of Science ®Google Scholar
• Moore LB, Goodwin B, Jones SA, et al. (2000). St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500–2
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Drocourt L, Fabre JM, et al. (2000). Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 58:361–72
   PubMed Web of Science ®Google Scholar
• Raucy JL, Lasker JM. (2010). Current in vitro high throughput screening approaches to assess nuclear receptor activation. Curr Drug Metab 11:806–14
   PubMed Web of Science ®Google Scholar
• Rew Y, Mcminn DL, Wang Z, et al. (2009). Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11beta-HSD1 inhibitors. Bioorg Med Chem Lett 19:1797–801
   PubMed Web of Science ®Google Scholar
• Ruggeri RB, Buckbinder L, Bagley SW, et al. (2015). Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acet amide (PF-06282999): a highly selective mechanism-based myeloperoxidase inhibitor for the treatment of cardiovascular diseases. J Med Chem 58:8513–28
   PubMed Web of Science ®Google Scholar
• Shukla SJ, Sakamuru S, Huang R, et al. (2011). Identification of clinically used drugs that activate pregnane X receptors. Drug Metab Dispos 39:151–9
   PubMed Web of Science ®Google Scholar
• Sinz M. (2015). Avoiding PXR and CAR activation and CYP3A4 enzyme induction. Topics Med Chem 9:159–90
   Google Scholar
• Sinz M, Kim S, Zhu Z, et al. (2006). Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375–88
   PubMed Web of Science ®Google Scholar
• Sinz M, Wallace G, Sahi J. (2008). Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J 10:391–400
   PubMed Web of Science ®Google Scholar
• Strayhorn VA, Baciewicz AM, Self TH. (1997). Update on rifampin drug interactions, III. Arch Intern Med 157:2453–8
   PubMed Web of Science ®Google Scholar
• Teo YL, Saetaew M, Chanthawong S, et al. (2012). Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat 133:703–11
   PubMed Web of Science ®Google Scholar
• Timsit YE, Negishi M. (2007). CAR and PXR: the xenobiotic-sensing receptors. Steroids 72:231–46
   PubMed Web of Science ®Google Scholar
• Tong EY, Kowalski M, Yip GS, Dooley MJ. (2014). Impact of drug interactions when medications are stopped: the often forgotten risks. Med J Aust 200:345–6
   PubMed Web of Science ®Google Scholar
• Ucar M, Neuvonen M, Luurila H, et al. (2004). Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 59:879–82
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. (2004). Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647–60
   PubMed Web of Science ®Google Scholar
• Wang W, Prosise WW, Chen J, et al. (2008). Construction and characterization of a fully active PXR/SRC-1 tethered protein with increased stability. Protein Eng Des Sel 21:425–33
   PubMed Web of Science ®Google Scholar
• Wang YM, Ong SS, Chai SC, Chen T. (2012). Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin Drug Metab Toxicol 8:803–17
   PubMed Web of Science ®Google Scholar
• Watkins RE, Maglich JM, Moore LB, et al. (2003). 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 42:1430–8
   PubMed Web of Science ®Google Scholar
• Watkins RE, Wisely GB, Moore LB, et al. (2001). The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292:2329–33
   PubMed Web of Science ®Google Scholar
• Williamson B, Lorbeer M, Mitchell MD, et al. (2016). Evaluation of a novel PXR-knockout in HepaRG(™) cells. Pharmacol Res Perspect 4:e00264
   PubMed Web of Science ®Google Scholar
• Xie W, Barwick JL, Simon CM, et al. (2000). Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev 14:3014–23
   PubMed Web of Science ®Google Scholar
• Zimmermann K, Wittman MD, Saulnier MG, et al. (2010). SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors. Bioorg Med Chem Lett 20:1744–8
   PubMed Web of Science ®Google Scholar